Search
Cerulenin
go.drugbank.com/drugs/DB01034ExperimentalIt is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus. … In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity.
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026. … Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.
Synonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamideAdenine
go.drugbank.com/drugs/DB00173ApprovedInvestigationalNutraceuticalA purine base and a fundamental unit of adenine nucleotides.
Mixtures: ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic), ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigationalThese therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen. … A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in
Luteinizing hormone
go.drugbank.com/drugs/DB14741ApprovedInvestigationalMixtures: MENOPUR 150 IU IM VE SC ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 5 ADET, Humegon Inj 75 I.U.Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14407ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Efluelda Tetra Injektionssuspension in einer Fertigspritze, VAXİGRİP 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 10 ADETInfluenza B virus B/Maryland/15/2016 BX-69A antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14559ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Efluelda Tetra Injektionssuspension in einer Fertigspritze, VAXİGRİP 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 10 ADETNilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigational), another tyrosine kinase inhibitor used as a first-line treatment for CML. … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec
Calcium ascorbate
go.drugbank.com/drugs/DB14483ApprovedNutraceuticalMixtures: Vc II, Procosa IICategories: Compounds used in a research, industrial, or household settingPatiromer
go.drugbank.com/drugs/DB09263ApprovedInvestigationalPatiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. … Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads.
Categories: Compounds used in a research, industrial, or household setting, Potassium Ion Binding Activity